67337-17-1

Upstream product

• 15679-27-3 (4S,5S)-4,5-bis(hydroxymethyl)cyclohexene 
• 100-39-0 benzyl bromide 
• 51096-08-3 (1S,2S)-cyclohex-4-ene-1,2-dicarboxylic acid 
• 137492-80-9 (1S,2S)-cyclohex-4-ene-1,2-dicarboxylic acid dimethyl ester 
• 109062-95-5 (1S,2S)-di-(-)-menthyl cyclohex-4-ene-1,2-dicarboxylate 
• 58124-49-5 (5aS,9aS)-3-phenyl-1,5,5a,6,9,9a-hexahydrobenzo[e][1,3]dioxepine 

Downstream Products

• 246518-21-8 (3S,4S)-3-(benzyloxymethyl)-4-(hydroxymethyl)cyclopentanone 
• 246518-22-9 (1S,3S,4S)-3-(benzyloxymethyl)-4-(hydroxymethyl)cyclopentanol 
• 66251-12-5 ((1R,6S)-6-Benzyloxymethyl-cyclohex-3-enyl)-acetic acid 
• 67312-13-4 ((1R,6S)-6-Benzyloxymethyl-cyclohex-3-enyl)-acetonitrile 
• 66251-11-4 Toluene-4-sulfonic acid (1S,6S)-6-benzyloxymethyl-cyclohex-3-enylmethyl ester 

Relevant academic research and scientific papers

ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF

The present invention relates to novel adenine based inhibitors of adenylyl cyclase of the formula: wherein X, L, R1, R2, R5 are those defined herein. Compounds of the present invention are useful to treat cardiovascular diseases. The present invention also relates to a method of preventing heart failure by administering an effective amount of compound according to the invention following vascular injury and reperfusion therapy.